Neonc Technologies Holdings, Inc.
NTHI Nasdaq Pharmaceutical Preparations Financials FY2024–FY2025
What Neonc Technologies Holdings, Inc. does
No business description yet.
- Legal name
- NEONC TECHNOLOGIES HOLDINGS, INC.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Accession · CIK
- 0001829126-26-002860
0001979414
Revenue and margins
Neonc Technologies Holdings, Inc. had $0.0M of revenue in fiscal 2025, down 51.8% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$20.9M in fiscal 2025, −52,159.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Neonc Technologies Holdings, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 26.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Neonc Technologies Holdings, Inc. can carry it.
| Fiscal year end | FY24 | FY25 |
|---|---|---|
| Cash and short-term investments | $0.1M | $0.1M |
| Interest coverage | −2.8x | −23.3x |
| Current ratio | 0.2x | 0.1x |
| Quick ratio | 0.2x | 0.1x |
| Total assets | $3.4M | $2.8M |
| Total liabilities | $8.9M | $20.3M |
| Shareholders' equity | −$5.5M | −$17.5M |
| Net debt (− = net cash) | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ |
| Return on assets rose | — | ✕ |
| Cash from operations exceeds net income | ✓ | ✓ |
| Debt fell relative to assets | — | — |
| Current ratio rose | — | ✕ |
| Share count didn't rise | — | ✕ |
| Gross margin rose | — | — |
| Revenue rose relative to assets | — | ✕ |
| F-score | — / 3 | 1 / 7 |
| Accruals ratio | −224.9% | −1,339.0% |
| Altman Z'' | −75.89 | −313.03 |
2 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Income statement | ||
| Revenue | $0.1M | $0.0M |
| Research and development | $3.0M | $3.6M |
| Operating income | −$7.1M | −$58.2M |
| Interest expense | $2.6M | $2.5M |
| Net income | −$11.9M | −$62.1M |
| Diluted EPS | −$0.69 | −$3.20 |
| Diluted shares | 0.02B | 0.02B |
| Cash flow | ||
| Cash from operations | −$4.2M | −$20.4M |
| Capital expenditure | — | $0.5M |
| Free cash flow | — | −$20.9M |
| Stock-based compensation | — | $35.6M |
| Balance sheet | ||
| Cash and short-term investments | $0.1M | $0.1M |
| Current assets | $2.2M | $1.4M |
| Current liabilities | $8.9M | $20.0M |
| Intangible assets | — | $0.5M |
| Total assets | $3.4M | $2.8M |
| Total liabilities | $8.9M | $20.3M |
| Shareholders' equity | −$5.5M | −$17.5M |
| Margins | ||
| Operating margin | −8,605.4% | −145,601.0% |
| Net margin | −14,335.5% | −155,365.5% |
| FCF margin | — | −52,159.8% |
| Returns | ||
| Return on capital employed | 129.7% | 338.3% |
| Return on assets | −348.2% | −1,991.6% |
| Growth | ||
| Revenue growth | — | −51.8% |
| Share count change | — | 26.9% |
| Financial health | ||
| Interest coverage | −2.8x | −23.3x |
| Current ratio | 0.2x | 0.1x |
| Quick ratio | 0.2x | 0.1x |
| Capital allocation | ||
| Capex / revenue | — | 1,250.0% |
| Stock comp / revenue | — | 88,887.8% |
| Quality scores | ||
| Piotroski F-score | — | 1.0 |
| Altman Z'' | −75.9 | −313.0 |
| Accruals ratio | −224.9% | −1,339.0% |
Source: SEC EDGAR XBRL filings (CIK 0001979414). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.